TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA

NYSELarge CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #878 of 2,925TOP 50%

Why it scores 60Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$4.14B

Quarter to Jun 30

Net income

$-576.00M

Quarter to Jun 30

Free cash flow

$307.00M

Quarter to Jun 30

Operating margin

-5.6%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$24.70B total
BlackRock, Inc.
$2.16B-1.9%
Harel Insurance Investments & Financial Services Ltd.
$1.63B+4.7%
Phoenix Financial Ltd.
$1.45B+0.4%
WCM INVESTMENT MANAGEMENT, LLC
$1.38B+1.2%
Clal Insurance Enterprises Holdings Ltd
$1.37B+5.6%
MENORA MIVTACHIM HOLDINGS LTD.
$1.35B+0.6%
Migdal Insurance & Financial Holdings Ltd.
$1.32B+2.7%
NORGES BANK
$1.09B--
FMR LLC
$1.03B-8.7%
Lingotto Investment Management LLP
$684.58M-27.2%
STATE STREET CORP
$641.57M+6.4%
Rubric Capital Management LP
$527.68M+2.1%
Capital World Investors
$424.72M+41.9%
Altshuler Shaham Ltd
$411.81M+8.8%
GEODE CAPITAL MANAGEMENT, LLC
$391.01M+9.9%
MEITAV INVESTMENT HOUSE LTD
$336.88MNew
NORTHERN TRUST CORP
$269.58M+4.2%
WELLINGTON MANAGEMENT GROUP LLP
$259.90M+5.8%
MORGAN STANLEY
$236.10M-6.2%
JPMORGAN CHASE & CO
$232.54M+3.2%
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$223.37M+362.5%
Alyeska Investment Group, L.P.
$212.01M+13.4%
GOLDMAN SACHS GROUP INC
$207.66M+27.0%
BESSEMER GROUP INC
$189.10M+28.3%
Polar Capital Holdings Plc
$176.61M+0.7%
See all 677 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TEVA

Earnings Per Share

13fpro.ai/company/TEVA

Loading ratio trend…

TEVA key financials by period

Reported revenue, net income and operating margin by fiscal year, from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual filings on SEC EDGAR.

TEVA PHARMACEUTICAL INDUSTRIES LTD reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$17.3B$1.4B12.5%
FY 2024$16.5B$-1.6B-1.8%
FY 2023$15.8B$-559.0M2.7%
FY 2022$14.9B$-2.4B-14.7%
FY 2021$15.9B$417.0M10.8%
FY 2020$16.7B$-4.0B-21.4%
Source: TEVA filings on SEC EDGAR →

Companies similar to TEVA

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

TEVA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in TEVA

2 transactions in TEVA reported by 2 members of Congress under the STOCK Act, most recent trade Jun 15, 2017. Reported transactions, not recommendations.

All Congress stock trades →

About TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA): stock profile, AI score and financials

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TEVA at 60.1/100 on a composite quality score built from its SEC filings, placing it at rank #878 of 2,925 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), TEVA PHARMACEUTICAL INDUSTRIES LTD reports quarterly revenue of $4.1B, net income of $-576.0M, an operating margin of -5.6%. Top institutional holders of TEVA by reported 13-F value include BlackRock, Harel Insurance Investments & Financial Services Ltd., Phoenix Financial Ltd., based on the most recent SEC filings. TEVA trades on the NYSE exchange and files with the SEC under CIK 818686. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TEVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TEVA PHARMACEUTICAL INDUSTRIES LTD directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 818686 →